Sacubitril/Valsartan: potential treatment for paediatric heart failure. (6th July 2018)

• Record Type: Journal Article
• Authors: Das, Bibhuti B.; Scholl, Frank; Vandale, Breanna; Chrisant, Maryanne
• Is Part Of: Cardiology in the young. Volume 28:Number 9(2018)
• Page Start: 1077
• Page End: 1081
• Publication Date: 2018-07-06
• Subjects: Paediatric heart failure, -- angiotensin receptor blocker, -- neprilysin inhibitor; Pediatric cardiology -- Periodicals; 618.9212
• DOI: 10.1017/S1047951118001014
• Languages: English
• ISSNs: 1047-9511

Abstract

Abstract: The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.